Skip to main content
INDP
NASDAQ Life Sciences

Shareholders Approve Massive Dilution, Control Change to David Lazar, and Reverse Stock Split Authority

Analysis by Wiseek.ai
Sentiment info
Negative
Importance info
9
Price
$2.063
Mkt Cap
$4.626M
52W Low
$1.52
52W High
$47.6
Market data snapshot near publication time

summarizeSummary

Indaptus Therapeutics shareholders approved the conversion of preferred stock into 96.4% of fully diluted common shares for David E. Lazar, effectively transferring control, and authorized a significant reverse stock split and a massive increase in authorized shares.


check_boxKey Events

  • Shareholder Approval for Control Change

    Stockholders approved the conversion of David E. Lazar's preferred stock into 111.0 million common shares, representing approximately 96.4% of the company's fully diluted common stock, effectively transferring control.

  • Reverse Stock Split Authorized

    The Board is now authorized to effect a reverse stock split with a ratio between 1-for-2 and 1-for-199, indicating significant concerns about the company's stock price.

  • Authorized Shares Increased

    The number of authorized common shares was increased to 1,000,000,000, providing substantial capacity for future equity issuance and potential dilution.

  • New Board Majority

    David E. Lazar's nominees now constitute a majority of the nine-member Board, solidifying his control over the company.


auto_awesomeAnalysis

This 8-K confirms the successful shareholder vote on critical proposals previously outlined in proxy statements. The approval of David E. Lazar's preferred stock conversion into 111.0 million common shares, representing approximately 96.4% of the company's fully diluted common stock, constitutes a definitive change of control and extreme dilution for existing shareholders. Furthermore, the authorization for a reverse stock split (up to 1-for-199) signals severe stock price weakness and potential delisting concerns, while the increase in authorized shares to 1 billion provides substantial headroom for future dilutive capital raises. These actions fundamentally reshape the company's ownership structure and financial future, following a series of related filings regarding the financing and board appointments.

At the time of this filing, INDP was trading at $2.06 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4.6M. The 52-week trading range was $1.52 to $47.60. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.

descriptionView Main SEC Filing

show_chartPrice Chart

Share this article

Copied!

feed INDP - Latest Insights

INDP
Apr 29, 2026, 4:05 PM EDT
Filing Type: SCHEDULE 13D/A
Importance Score:
7
INDP
Apr 22, 2026, 9:59 PM EDT
Filing Type: 8-K
Importance Score:
7
INDP
Apr 03, 2026, 12:00 PM EDT
Filing Type: 8-K
Importance Score:
8
INDP
Mar 30, 2026, 9:46 PM EDT
Filing Type: SCHEDULE 13D
Importance Score:
9
INDP
Mar 24, 2026, 4:30 PM EDT
Filing Type: 8-K
Importance Score:
10
INDP
Mar 24, 2026, 4:05 PM EDT
Filing Type: SCHEDULE 13D/A
Importance Score:
9
INDP
Mar 24, 2026, 4:02 PM EDT
Filing Type: 4
Importance Score:
8
INDP
Mar 17, 2026, 4:30 PM EDT
Filing Type: 10-K
Importance Score:
9
INDP
Mar 02, 2026, 5:20 PM EST
Filing Type: SCHEDULE 13D
Importance Score:
10
INDP
Feb 27, 2026, 4:05 PM EST
Filing Type: 8-K
Importance Score:
9